Abstract 15881: GlycA Predicts Vascular Inflammation by 18-FDG PET/CT Beyond hsCRP in Psoriasis at Baseline and 1-year Follow-up

IntroductionRecent studies suggest that hsCRP may not accurately capture CV risk in patients with inflammatory disorders such as psoriasis (PSO). GlycA, a novel inflammatory biomarker, predicted future CV events in large population based studies. Whether GlycA associates with subclinical CVD and how it performs in CVD assessment beyond hsCRP in PSO is unknown.HypothesisGlycA would associate with aortic vascular inflammation (VI), assessed as target-to-background ratio (TBR), by FDG PET/CT in PSO.MethodsConsecutive PSO patients (n=151) underwent FDG PET/CT scans at baseline as part of a large cohort study (NCT01778569). 95 patients also underwent repeat scans at 1-year. GlycA was measured by nuclear magnetic resonance (LabCorp). Labs were measured in a certified clinical research facility. Statistical analyses included multivariable regression and ROC modeling.ResultsPSO patients were middle aged, at low Framingham risk, but had significant cardiometabolic dysfunction (Table). While hsCRP did not associate with TBR (β=0.03, p=0.7), GlycA was strongly associated with TBR beyond traditional risk factors and hsCRP in PSO (β=0.22, p